Addiction biology
May 1, 2022
Feng Li, Han Du, Bo Wu et al.
16 citations
The drug 2-fluorodeschloroketamine (2-FDCK), a ketamine substitute used by drug abusers, shows abuse potential comparable to ketamine. In mice, 2-FDCK at 3 mg/kg induced conditioned place preference, similar to ketamine. Acute injections at 30 mg/kg increased locomotor activity, and repeated treatments led to locomotor sensitization after withdrawal. 2-FDCK supported self-administration at 0.5 mg/kg/infusion, matching ketamine, with peak seeking at 1 mg/kg. In drug discrimination tests, 2-FDCK dose-dependently substituted for ketamine with comparable potency. These findings indicate that 2-FDCK has an abuse potential similar to ketamine.
Neuroscience research
July 1, 2025
Kaixi Li, Nan Li, Yuanyuan Chen et al.
1 citation
Three synthetic tryptamines—AMT, 5-MeO-AMT, and 5-MeO-DiPT—alter levels of dopamine and serotonin and their metabolites in specific rat brain regions, including the prefrontal cortex, nucleus accumbens, dorsolateral striatum, and hippocampus. The effects vary by brain region and compound, with dopamine and serotonin systems playing key roles. These findings provide insight into the neurochemical actions of tryptamine hallucinogens.
Behavioural pharmacology
July 7, 2025
Kaixi Li, Nan Li, Yuanyuan Chen et al.
Three synthetic tryptamines—AMT, 5-MeO-AMT, and 5-MeO-DiPT—showed acute toxic effects, reduced movement, and triggered head-twitch responses (a sign of hallucinogenic-like behavior) in mice. Pretreatment with a low dose of M100907, a 5-HT2A receptor antagonist, blocked the head-twitch responses caused by all three substances. The findings indicate these compounds are toxic, inhibit locomotor activity, and have hallucinogenic properties, providing experimental data to support future regulation and mechanistic research.